← Back to Clinical Trials
Recruiting NCT07624058

NCT07624058 Erector Spina Plane Block Versus Modified Thoracoabdominal Nerve Block After Laparoscopic Cholecystectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07624058
Status Recruiting
Phase
Sponsor Alexandria University
Condition Erector Spinae Block
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2026-04-01
Primary Completion 2026-12-01

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
bilateral ESP blockbilateral M-TAPA block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2026-04-01 with a primary completion date of 2026-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

direct comparisons between ESPB and M-TAPA for postoperative analgesia after LC remain limited. This is an important area of clinical interest because the two blocks differ significantly in their anatomical targets, mechanism of analgesia, and likely dermatomal coverage. The ESPB provides analgesia through paravertebral spread affecting both dorsal and ventral rami, thereby offering posterior and visceral pain relief, whereas M-TAPA directly targets the thoracoabdominal nerves, resulting in better anterior and lateral abdominal wall analgesia. Understanding which technique offers superior or more balanced analgesia could help to optimise regional anaesthesia strategies in LC and to improve patient outcomes.

Eligibility Criteria

Inclusion Criteria: * Age: between 30 - 65 * American Society of Anaesthesiologists physical status: I- III * Body mass index: 18-35 kg.m-2 Exclusion Criteria: * Patient Refusal * Allergy to local anaesthetic agents. * Skin infection at the site of injection. * Coagulopathy. * Diabetes Mellitus

Contact & Investigator

Central Contact

sarah m elgamal, MD

✉ sarahelgamal1990@yahoo.com

📞 01005496440

Principal Investigator

sarah m elgamal, MD

PRINCIPAL INVESTIGATOR

Alexandria University

Frequently Asked Questions

Who can join the NCT07624058 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 65 Years, studying Erector Spinae Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07624058 currently recruiting?

Yes, NCT07624058 is actively recruiting participants. Contact the research team at sarahelgamal1990@yahoo.com for enrollment information.

Where is the NCT07624058 trial being conducted?

This trial is being conducted at Alexandria, Egypt.

Who is sponsoring the NCT07624058 clinical trial?

NCT07624058 is sponsored by Alexandria University. The principal investigator is sarah m elgamal, MD at Alexandria University. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology